"Drug Evaluation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
| Descriptor ID |
D004341
|
| MeSH Number(s) |
E05.337.425
|
| Concept/Terms |
Drug Evaluation- Drug Evaluation
- Drug Evaluations
- Evaluation, Drug
- Evaluations, Drug
- Evaluation Studies, Drug
- Drug Evaluation Studies
- Drug Evaluation Study
- Evaluation Study, Drug
- Studies, Drug Evaluation
- Study, Drug Evaluation
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation".
This graph shows the total number of publications written about "Drug Evaluation" by people in this website by year, and whether "Drug Evaluation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Evaluation" by people in Profiles.
-
Silberstein SD, Cohen JM, Yeung PP. Fremanezumab for the preventive treatment of migraine. Expert Opin Biol Ther. 2019 08; 19(8):763-771.
-
Piccini JP, Clark RL, Kowey PR, Mittal S, Dunnmon P, Stockbridge N, Reiffel JA, Turakhia MP, Ziegler PD, Kleiman RB, Ismat F, Sager P. Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. Am Heart J. 2017 May; 187:156-169.
-
Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 01; 196:127-31.
-
Yannuzzi NA, Klufas MA, Quach L, Beatty LM, Kaminsky SM, Crystal RG, D'Amico DJ, Kiss S. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015 Jan; 133(1):32-9.
-
Xu X, Farach-Carson MC, Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv. 2014 Nov 15; 32(7):1256-1268.
-
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 01; 118(11):2944-51.
-
Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011 Feb; 66(2):192-6.
-
Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2010 Feb; 19(2):305-10.
-
Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, Valentin JP, Vargas HM, Krucoff MW. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J. 2009 Sep; 158(3):317-26.
-
Sarapa N, Gussak I, Vajdic B, George S, Hadzievski L, Francom SF, Kowey P. Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. J Electrocardiol. 2009 Jul-Aug; 42(4):358-66.